Chugai Pharmaceutical (OTCMKTS:CHGCY) Sees Strong Trading Volume – Still a Buy?

Shares of Chugai Pharmaceutical Co., Ltd. Unsponsored ADR (OTCMKTS:CHGCY) saw strong trading volume on Thursday . Approximately 495,485 shares changed hands during mid-day trading, an increase of 111% from the previous session’s volume of 234,746 shares.The stock last traded at $23.43 and had previously closed at $23.66.

Wall Street Analyst Weigh In

Several brokerages have weighed in on CHGCY. Zacks Research upgraded shares of Chugai Pharmaceutical to a “hold” rating in a research note on Friday, May 29th. The Goldman Sachs Group raised shares of Chugai Pharmaceutical from a “hold” rating to a “buy” rating in a report on Monday. Finally, Smbc Nikko Sec. upgraded Chugai Pharmaceutical to a “strong-buy” rating in a research note on Wednesday, February 25th. Two equities research analysts have rated the stock with a Strong Buy rating, one has given a Buy rating and one has issued a Hold rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Buy”.

Chugai Pharmaceutical Price Performance

The firm has a market capitalization of $77.15 billion, a P/E ratio of 26.04 and a beta of 0.58. The stock has a fifty day simple moving average of $25.14 and a two-hundred day simple moving average of $27.06.

Chugai Pharmaceutical (OTCMKTS:CHGCY) last issued its quarterly earnings results on Friday, April 24th. The company reported $0.22 earnings per share (EPS) for the quarter. The firm had revenue of $2.05 billion for the quarter. Chugai Pharmaceutical had a return on equity of 22.90% and a net margin of 34.98%. As a group, sell-side analysts expect that Chugai Pharmaceutical Co., Ltd. Unsponsored ADR will post 0.98 EPS for the current fiscal year.

About Chugai Pharmaceutical

Chugai Pharmaceutical Co, Ltd. is a Japan-based biopharmaceutical company headquartered in Tokyo that focuses on the discovery, development, manufacture and marketing of prescription medicines. The company develops both biologics and small-molecule therapies, with particular emphasis on oncology and immunology as well as treatments for bone and metabolic disorders. Chugai’s activities span the full drug lifecycle from early research and clinical development through regulatory approval, manufacturing and post-marketing support.

Chugai is known for its research-driven approach and its work on monoclonal antibodies and other biologic therapeutics.